Table 1.
Effect of ellagic acid (Ella), ellagic acid nanoparticles (Ella NPs), metformin, and their combination plasma lipid profile measured after 9 weeks of treatment.
| Group | TC (mg/dl) | TG (mg/dl) | HDL (mg/dl) | LDL (mg/dl) | VLDL (mg/dl) |
|---|---|---|---|---|---|
| Control | 90 ± 9.3 | 58 ± 6.3 | 37 ± 1.1 | 36 ± 6.8 | 11 ± 1.2 |
| HFD | 94 ± 6.1 | 93 ± 14.7 a | 23 ± 2.1 a | 53 ± 6.8 | 19 ± 2.9 a |
| Diabetic | 90 ± 8.8 | 126 ± 17.5 a | 28 ± 3.6 a | 42 ± 9.5 | 25 ± 3.4 a |
| Metformin | 83 ± 13.0 | 90 ± 10.0 b | 27 ± 2.6 | 49 ± 13.5 | 18 ± 1.9 b |
| Ella | 86 ± 2.7 | 51 ± 2.9 b, c | 25 ± 1.7 | 51 ± 0.8 | 10 ± 0.4 b, c |
| Ella + Metformin | 73 ± 12.4 | 60 ± 2.3 b, c | 27 ± 4.3 | 34 ± 8.3 | 12 ± 0.4 b, c |
| Ella NPs | 60 ± 4.7 b, c | 62 ± 3.3 b, c | 25 ± 1.8 | 26 ± 2.9 b, c | 12 ± 0.6 b, c |
| Ella NPs + Metformin | 68 ± 10.0 b, c | 43 ± 2.7 b, c | 26 ± 2.9 | 33 ± 6.6 b, c | 9 ± 0.9 b, c |
Results are presented as mean ± SD.
TC: total cholesterol; TG: triglyceride; HDL: high-density lipoprotein; LDL: low-density lipoprotein; VLDL: very-low-density lipoprotein.
a
Significant relative to control.
b
Significant relative to diabetic.
c
Significant relative to metformin. (P < 0.05).